Breaking News: CDC Panel Recommends Moderna and Johnson & Johnson COVID-19 Vaccine Boosters for Eligible Patients

Oct. 21, 2021

Today, the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on two interim recommendations that will greatly expand the number of people who are eligible to receive COVID-19 booster doses.

ACIP members voted to recommend a single 50 mcg booster dose of Moderna’s COVID-19 vaccine six months after completion of the primary series, in the same risk groups for whom the CDC previously recommended a booster dose of Pfizer-BioNTech, under the FDA’s emergency use authorization (EUA).

- People 65 years and older and residents in long-term care settings should receive a booster shot at least 6 months after their primary series
- People aged 50–64 years with underlying medical conditions should receive a booster shot at least 6 months after their primary series
- People aged 18–49 years with underlying medical conditions may receive a booster shot at least 6 months after their primary series, based on their individual benefits and risks
- People aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot at least 6 months after their primary series, based on their individual benefits and risks

They also voted to recommend a single COVID-19 vaccine booster dose for people 18 years of age and older two months after receipt of the initial Johnson & Johnson dose, under the Food and Drug Administration’s (FDA) EUA.

The CDC is expected to issue guidance soon based on ACIP’s recommendations.

On Wednesday afternoon, the FDA amended the emergency use authorizations of Moderna and Johnson & Johnson’s COVID-19 vaccines to allow for the use of a single booster dose of these vaccines in eligible populations. The FDA also authorized the use of mix-and-match booster doses for all authorized or approved COVID-19 vaccines after reviewing clinical trial data from the National Institute of Allergy and Infectious Diseases on heterologous booster doses. The CDC is expected to issue clinical considerations on the mixing and matching of booster doses.

These actions followed last week’s two-day meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee, which voted in favor of a booster dose of Moderna’s COVID-19 vaccine for eligible patients and a booster dose of Johnson & Johnson’s COVID-19 vaccines for people 18 years and older at least two
months after a single-dose primary vaccination. Nearly 100 million patients are eligible for a booster dose of the over 190 million fully vaccinated in the U.S.

Additionally, a CDC Clinician Outreach and Communication Activity call will be held Tuesday, Oct. 26 at 2 p.m. ET to provide an overview of the most recent recommendations for administering COVID-19 booster vaccines.

**ACIP Vote #1**

**Interim Recommendation**

A single COVID-19 vaccine booster dose is recommended ≥6 months after completion of an mRNA primary series, in the same risk groups for whom CDC recommended a booster dose of Pfizer-BioNTech, under the FDA’s Emergency Use Authorization

---

**ACIP Vote #2**

**Interim Recommendation**

A single COVID-19 vaccine booster dose is recommended for persons aged ≥18 years, ≥2 months after receipt of the initial Janssen dose, under the FDA’s Emergency Use Authorization